These are 2019’s most influential clinical executives
A leading health care trade publication has released its list of top 50 clinical executives. Twenty-one share a common trait: AMA membership.
New AMA president: Time for physicians to create history together
In ascending to one of medicine’s highest offices, new AMA president Patrice A. Harris, MD, MA, has completed an unlikely journey.
Time to scrutinize PBMs’ outsized role in Rx decision-making
The AMA calls for transparency and oversight of pharmacy benefit managers’ (PBM) operations.
AMA to Congress: Patients pay painful price for high drug costs
AMA leader tells of a patient who relies on an older drug that rose in price by 400% to about $80,000 a year. Share your stories to advance drug-pricing transparency.
AMA: Trump administration requiring pricing information in TV drug ads
The Trump Administration has taken a step in the right direction requiring pricing information in television advertising of prescription drugs.
The truth behind drug prescription pricing
Spending on prescription drugs is on the rise in the United States, but lack of oversight on drug pricing offers no answers for price fluctuations.
AMA applauds congressional action on prescription drug transparency
The AMA believes in transparency in prescription drug pricing, and we are pleased the House Ways & Means Committee moved the issue forward.
How are prescription drug prices determined?
Congress has put drug prices under its microscope. The scrutiny is new, but the conversation is the same: Drugmakers, pharmacy benefit managers and payers set prices but never explain how.
Quick Take: Action on drug pricing gets massive bipartisan support
Legislation to speed generic drugs to market, improving price transparency and boost competition could soon come to the House floor.